Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 15/20 | 0.48 |
| ▸ | INSR | P06213 | 5/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 3/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32690425 | 0.89 | ALK (0.53) | ALKCDK7CDK9METPTK2 | |
| SCHEMBL31251235 | 0.88 | ALK (0.54) | ALKINSRCDK7CDK9MET | |
| SCHEMBL32690398 | 0.87 | CDK7 (0.53) | ALKINSRCDK7CDK9MET | |
| SCHEMBL32690307 | 0.86 | ALK (0.51) | ALKINSRCDK7CDK9MET | |
| SCHEMBL32690358 | 0.85 | CDK7 (0.53) | ALKINSRCDK7CDK9MET | |
| SCHEMBL32690300 | 0.84 | ALK (0.50) | ALKINSRCDK7CDK9MET | |
| SCHEMBL32690426 | 0.83 | CDK7 (0.55) | ALKINSRCDK7CDK9MET | |
| SCHEMBL32690356 | 0.83 | ALK (0.49) | ALKINSRCDK7CDK9MET | |
| SCHEMBL32690395 | 0.83 | CDK7 (0.53) | ALKINSRCDK7CDK9MET | |
| SCHEMBL31251255 | 0.79 | CDK7 (0.52) | ALKINSRCDK7CDK9MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD (US) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | ALK, ERBB2, ERBB3 | ALK 1/4885INSR 314/4885CDK7 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.